Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stereoselective pharmacokinetics and CYP2C19-genotyping as outcome predictors of omeprazole therapy in GERD
2006-002346-11Phase 4Completed
- Sponsor
- Medical Faculty Magdeburg
- Start
- Sep 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of omeprazole in gastroesophageal reflux disease (GERD), sponsored by Medical Faculty Magdeburg. Primary endpoint: Gastric acid suppression measured by pH-metry. Started Sep 2006; status: completed.
02
Drugs
omeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2006-002346-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002346-11.